Timing is everything: Towards classification criteria for early-stage symptomatic knee osteoarthritis.

Competing Interests: Declaration of Competing Interest LKL reports support from the Canadian Institutes of Health Research Doctoral Award, and grant funding from a Physician Services Incorporated (PSI) Resident Grant. JWL reports a Pfizer research grant completed in 2021, unrelated to this work. QW reports support from Osteoarthritis and Cartilage as an Associate Editor for statistics. CTA reports grant funding and consulting/honoraria from Abbvie, Novartis, Pfizer, and Servier. ME reports grant funding from the Swedish Research Council, ERC, ALF, Kock Foundations, Gustav V 80 Year B-day Foundation, NORDFORSK, FOREUM, Foundation for Support to People With Movement Disability in Skåne, Österlund Foundation, SUS donations, consulting from Cellcolabs AB, and a leadership role as the OARSI President-elect. IKH reports consulting fees from Abbvie, GSK, and Grünenthal, and a leadership role as the OARSI Board of Directors Secretary. LSL reports consulting/honoraria from Arthro Therapeutics AB, Sweden, and participation on a DSMB board for AstraZeneca. JR reports a leadership role on the OARSI Ethics and Governance Committee, Nominating Committee. AT reports support from Osteoarthritis and Cartilage as an Associate Editor for statistics. TN reports grant funding from NIH, grant funding and consulting/honoraria from Pfizer/Lilly, Regeneron, and Novartis, and support from Osteoarthritis and Cartilage as a Deputy Editor. All other authors report no competing interests.